Hepatitis C Lab Testing Comparison Study
Status
Conditions
Treatments
Details and patient eligibility
About
Hepatitis C (HCV) HCV antibody assays are the standard of care test used to screen for HCV, but confirmation of acute infection is relegated in the current US guidelines to polymerase chain reaction (PCR) which often takes multiple days and may result in a loss to follow up and treatment, especially in high prevalence populations. HCV core antigen is a new, research use only immunoassay intended for use on the Abbott Alinity i system, an FDA-cleared instrument for clinical chemistry and immunoassay testing. The aim of the study is to evaluate the 48-hour stability of HCV core antigen in fresh serum and plasma specimens collected from individuals with a detectable HCV viral load (HCL VL), as per a recent antibody assay test, under multiple specimen storage conditions mirroring those employed in clinical laboratories.
Full description
This study seeks to test the stability of a novel method of hepatitis-C testing called HCV core antigen testing. This will be accomplished by prospectively consenting patients who have had a recent, positive standard of care HCV viral load test, and drawing additional blood to conduct HCV core antigen testing within the infectious period. Viral load amount of the core antigen test will be recorded at baseline and subsequent timepoints. Stability is defined as <10% change from baseline and will be recorded at various timepoints up to 144 hours post-draw. Stability will also be tested at room temperature vs. refrigerated storage and on the gel vs. off the gel processing techniques. This information is necessary to ensure HCV core antigen is sufficiently stable following specimen collection to enable robust, accurate, and precise measurement using the HCV core antigen assay.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Able to provide informed consent
- Had detectable HCV VL in a standard of care Hepatitis C RNA Quantitative test
- Initial hepatitis C VL testing took place at any HealthPartners lab
- Able to undergo a study blood draw within 3 weeks of initial hepatitis C VL testing
- Ability to sign e-consent prior to presenting for a study lab draw
Exclusion criteria
- Age <18 years
- On the HealthPartners research opt-out list
- HCV VL not detectable at follow-up lab draw (screen fail)
Trial design
Primary purpose
Allocation
Interventional model
Masking
25 participants in 1 patient group
Trial contacts and locations
Loading...
Central trial contact
Ian Gunsolus
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal